Group 1 - The core viewpoint of the news is that Yiming Anke-B (01541) has made significant progress in the development of innovative drugs for autoimmune diseases, with the acceptance of the clinical trial application for IMM0306S by the National Medical Products Administration (NMPA) [1] - IMM0306S is a subcutaneous formulation of the bispecific antibody targeting CD47 and CD20, developed based on the company's core product IMM0306, which is the world's first CD47xCD20 bispecific molecule to enter clinical stages [1] - The stock price of Yiming Anke-B increased by nearly 4%, with a trading volume of 3.1192 million Hong Kong dollars, reflecting positive market sentiment following the announcement [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Anke presented data from the I/II clinical study of IMM0306 combined with lenalidomide for relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% [2] - The safety profile of the combination therapy was reported to be manageable, with no risk of cytokine release syndrome, indicating a promising new immunotherapy strategy for a currently incurable disease with limited treatment options [2] - The ongoing I/II phase study provides hope for patients who have failed at least one line of anti-CD20 monoclonal antibody treatment [2]
港股异动 | 宜明昂科-B(01541)涨近4% 自研阿沐瑞芙普α皮下制剂IMM0306S临床研究申请获受理